KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBIT (2016 - 2026)

West Pharmaceutical Services has reported EBIT over the past 18 years, most recently at $177.1 million for Q1 2026.

  • Quarterly EBIT rose 65.51% to $177.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $655.0 million through Mar 2026, up 18.21% year-over-year, with the annual reading at $584.9 million for FY2025, 2.63% up from the prior year.
  • EBIT was $177.1 million for Q1 2026 at West Pharmaceutical Services, up from $156.6 million in the prior quarter.
  • Over five years, EBIT peaked at $228.4 million in Q2 2022 and troughed at $107.0 million in Q1 2025.
  • The 5-year median for EBIT is $160.9 million (2023), against an average of $161.3 million.
  • Biggest five-year swings in EBIT: crashed 30.85% in 2024 and later surged 65.51% in 2026.
  • Tracing WST's EBIT over 5 years: stood at $129.7 million in 2022, then increased by 24.06% to $160.9 million in 2023, then fell by 0.81% to $159.6 million in 2024, then dropped by 1.88% to $156.6 million in 2025, then rose by 13.09% to $177.1 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at $177.1 million, $156.6 million, and $167.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.